{
  "docId": "019de071-753f-7227-aa1d-36a319c59353",
  "docSlug": "7013d0966bfedd0d757b9fa24a480455",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 34 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 34,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "timeline",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a chronological progression (Today, 2022, Future) to frame the drug's market expansion.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de071-753f-7227-aa1d-36a319c59353/20",
  "deckHref": "/decks/019de071-753f-7227-aa1d-36a319c59353",
  "deckJsonHref": "/decks/019de071-753f-7227-aa1d-36a319c59353.json",
  "deckAnchorHref": "/decks/019de071-753f-7227-aa1d-36a319c59353#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.75,
        "y": 0.5
      },
      "kind": "image",
      "text": "Enhertu vial",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a28a8680-38e5-4dd2-8661-4e5cc3ca7b69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.35,
        "y": 0.26
      },
      "kind": "list",
      "text": "2022: 2nd-line mBC. DESTINY-Breast03 unprecedented benefit, consistent efficacy, safety profile supports extended duration.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5430b615-926a-4312-98a3-d54cc1ce30c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.67,
        "y": 0.26
      },
      "kind": "list",
      "text": "Future: earlier settings, combinations. Efficacy/safety supports 1st line/adjuvant, curative intent, option for every HER2+ patient.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e090afb-8e95-4c66-aee7-0c4e7ddca31f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.03,
        "y": 0.26
      },
      "kind": "list",
      "text": "Today: 3rd-line+ mBC. Strong launch trajectory, >7,000 patients treated, partnering with HCPs.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8da646f-e6f9-44fc-8e6c-ebebe44ced52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. UK National Health Service – Cancer Drugs Fund, AstraZeneca market studies.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e2c7c30-751d-4aaf-897f-5b802badede4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Enhertu: a new standard of care for patients with HER2-positive metastatic breast cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c1797a6-1cce-474b-8c84-58068836c189",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "1d018572-6ef8-4cc3-8729-23ac13ca4666",
      "evidence": "The slide organizes content into three chronological phases: Today, 2022, and Future.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 17,
      "beatId": "b84365e9-a163-4557-b2fe-beb8ac4c4175",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Key takeaways and future prospects for Enhertu",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}